CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bambusa Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bambusa Therapeutics, Inc.
22 Boston Wharf Road, Floor 7
Phone: (617) 848-6188p:617 848-6188 BOSTON, MA  02210  United States Ticker: BBTXBBTX
Business Summary
Bambusa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on developing long-acting precision bispecific antibodies designed for care in immunology and inflammation (I&I) and improving patient quality of life. It uses third-party, advanced antibody engineering to create long-acting bispecific antibodies that combine clinically and commercially validated biologic pathways into a single molecule formulated for high-concentration subcutaneous (SubQ) delivery. Its lead product candidate, BBT001, is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated pathways, interleukin-4 receptor alpha and interleukin-31, is designed to simultaneously address core Type 2 inflammation and chronic itch, the two defining burdens of atopic dermatitis (AD) and other inflammatory skin diseases. BBT001 is engineered using validated half-life extension technology with the goal of enabling extended dosing intervals.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairperson, President, Chief Executive Officer, Co-Founder ShanshanXu 43 3/14/2024 3/14/2024
Co-Founder, Independent Director HelmutJeggle 56 6/1/2024 6/1/2024
Co-Founder, Chief Development Officer ThangHo 42 3/1/2026 10/1/2025
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Bambusa (Beijing) Therapeutics Co., Ltd.
Bambusa Securities Corporation
Bambusa Therapeutics Pty Ltd
BBTX
Entity Legal Name

General Information
Number of Employees: 30 (As of 9/30/2026)
Outstanding Shares: 50,942,430 (As of 6/30/2026)
Stock Exchange: NASD
Federal Tax Id: 992083913
Fax Number: (302) 655-5049


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 14, 2026